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A 49-year-old female with Adriamycin induced cardiomyopathy presented with 
decompensated biventricular congestive heart failure.  Despite multiple Inotropes, the patient’s 
hemodynamics deteriorated and she underwent veno-arterial extracorporeal membrane 
oxygenation (VA-ECMO) placement as a bridge to decision.  Pre-ECMO workup showed liver 
dysfunction with elevated total bilirubin of 5.9 mg/dl, normal liver enzymes and liver ultrasound 
image.  Tentative diagnosis of “end-stage liver failure” was made without a biopsy. 
Shortly after initiation of ECMO, the patient developed massive hemoptysis which was 
successfully managed with continuation of ECMO and ventilator management. 1  The patient’s 
total bilirubin continued to increase to peak of 56 mg/dl on ECMO day #9 (Figure 1). Molecular 
adsorbent recirculating system (MARS) was initiated on ECMO day 9 thru 14.  The bilirubin 
improved dramatically with MARS.  Liver biopsy performed while on ECMO provided a 
definitive diagnosis of cholestasis without cirrhosis.  The patient underwent Heart Mate II left 
ventricular assist device (LVAD) placement and ECMO removal on ECMO day 20. There was no 
further episode of liver failure, and the patient was eventually discharged from hospital. 
 
VA-ECMO is a support therapy for the patients with profound cardiac and/or respiratory 
failure, and its outcomes are closely related with end-organ recovery. 2  Non-survivors of ECMO 
follow a common pathway of development of intractable and progressive multi-organ 
dysfunction. Death can rapidly follow the development of liver dysfunction.  Current therapy of 
liver failure superimposed on cirrhosis is limited to treat the precipitating event; if the 
precipitating event can be eliminated, the liver can recover to its previous compensated state.  
Patient with liver failure accumulate toxic molecules and accumulation of these substances may 
induce encephalopathy, hypotension, renal failure, macrophage dysfunction, and/or inhibition of 
hepatocyte recovery.  
MARS is a cell-free extracorporeal liver support device based on the principle of albumin 
dialysis. 3  Blood is perfused through a specific membrane dialyzer that uses 20% albumin as a 
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molecular adsorbent that is re-circulated and perfused in-line through charcoal and anion 
exchanger columns.  Toxic molecules accumulated in the plasma can be eliminated by passage of 
blood or plasma over sorbent columns since most of these molecules are lipophilic and albumin 
bound.  The molecules which can be removed by MARS include bile acids, conjugated bilirubin, 
aromatic amino acids, medium chain fatty acids, mercaptans, and cytokines.  MARS not only 
remove selectively albumin bound substances but also MARS will eliminate water soluble toxins 
such as ammonia, creatinine. 3  Removal of these toxins by MARS may preserve end organ 
functions and decreased toxin molecule levels to facilitate organ recovery. 4 
Previously Peek reported that no patient survived from ECMO with MARS if the 
bilirubin was greater than 23 mg/dl (400 umol/L). 3  The peak bilirubin of our patient was 56 
mg/dl (957 umol/L).  A decrease in serum bilirubin for three consecutive days was the primary 
end point of MARS support on this patient.  The bilirubin level remained stable and did not 
increase after completion of MARS treatment.  Liver biopsy confirmed reversible pathology of 
liver.  At this point, this patient’s end-organ (liver) dysfunction was resolving.  The right 
ventricular function was recovered while on ECMO and no longer required biventricular support.  
Chronic left ventricular failure necessitated implantable LVAD.  MARS was initiated as a bridge 
to the decision to LVAD, eliminating elevated bilirubin without adverse effects.  Retrospective, 
the liver dysfunction may have been transient although the peak serum bilirubin level was fatally 
high.  The LVAD implantation was prohibited until hepatic failure was resolved with MARS. 
 4 
Disclosure statement 
All of the listed authors indicated no potential conflict of interest. 
 5 
References 
 
1
 Harrison M, Cowan S, Cavarocchi N, Hirose H.  Massive hemoptysis on veno-arterial 
extracorporeal membrane oxygenation.  Eur J Cardiothorac Surg. 2012 Mar 30. [Epub ahead of 
print]. 
2
 Schwarz B, Mair P, Margreiter J, et al.  Experience with percutaneous venoarterial 
cardiopulmonary bypass for emergency circulatory support.  Crit Care Med 2003; 31: 758-64. 
3
 Peek GJ, Killer HM, Sosnowski MA, Firmin RK.  Modular extracorporeal life support for 
multiorgan failure patients.  Liver. 2002;22:69-71. 
4
 El Banayosy A, Kizner L, Schueler V, Bergmeier S, Cobaugh D, Koerfer R.  First use 
of the Molecular Adsorbent Recirculating System technique on patients with hypoxic 
liver failure after cardiogenic shock.  ASAIO J.  2004;50:332-7. 
 6 
Legends of Figures 
Figure 1: Total bilirubin was significantly improved after molecular adsorbents recirculating 
system (MARS) during extracorporeal membrane circulation (ECMO), which was followed by 
left ventricular assist device (LVAD) 
placement.
 
